Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Completed
Actelion
Phase 2
2015-12-14
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on
diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood
pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood
pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral
regimen of 4 doses of ACT-132577.
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Completed
Idorsia Pharmaceuticals Ltd.
Phase 2
2015-12-14
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on
diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood
pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood
pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral
regimen of 4 doses of ACT-132577.
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
Active, not recruiting
Janssen Biotech, Inc.
Phase 3
2018-06-18
The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new
drug, when added to other anti-hypertensive drugs of patients with difficult to control
(resistant) high blood pressure (hypertension), and to show that blood pressure reduction is
kept for long period of time.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.